Docoh
Loading...

CRL Charles River Laboratories International

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

Company profile

Ticker
CRL
Exchange
Website
CEO
James Foster
Employees
Location
Fiscal year end
Former names
CHARLES RIVER LABORATORIES HOLDINGS INC, CHARLES RIVER LABORATORIES INTERNATIONAL INC
SEC CIK
Subsidiaries
Charles River Laboratories, Inc. • Charles River UK Limited • Charles River Laboratories Saint‑Constant S.A. • Charles River Holdings LLC • Ballardvale C.V. • Charles River Nederland B.V. • Charles River Laboratories Holding SAS • Charles River Laboratories France-C.R.L.F. SAS • Charles River Laboratories España SA • Charles River Laboratories Japan, Inc. ...
IRS number
61397316

CRL stock data

(
)

Calendar

4 Aug 21
24 Oct 21
26 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 227.49M 227.49M 227.49M 227.49M 227.49M 227.49M
Cash burn (monthly) 81.18M 14.71M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 322.18M 58.39M n/a n/a n/a n/a
Cash remaining -94.69M 169.1M n/a n/a n/a n/a
Runway (months of cash) -1.2 11.5 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
14 Sep 21 Girshick Birgit Common Stock Sell Dispose S No Yes 439.9 2,344 1.03M 27,602
13 Sep 21 Girshick Birgit Common Stock Sell Dispose S No Yes 442.73 7 3.1K 29,946
13 Sep 21 Girshick Birgit Common Stock Sell Dispose S No Yes 442.15 72 31.83K 29,953
13 Sep 21 Girshick Birgit Common Stock Sell Dispose S No Yes 441.655 2 883.31 30,025
31 Aug 21 Massaro George Common Stock Sell Dispose S No No 442.9883 983 435.46K 4,855
31 Aug 21 Massaro George Common Stock Sell Dispose S No No 442.1592 1,556 688K 5,838
31 Aug 21 Massaro George Common Stock Option exercise Acquire M No No 164.24 2,539 417.01K 7,394
31 Aug 21 Massaro George Stock Options Common Stock Option exercise Dispose M No No 164.24 2,539 417.01K 0
16 Aug 21 Victoria L Creamer Common Stock Sell Dispose S No No 415.243 6,917 2.87M 6,386
16 Aug 21 Victoria L Creamer Common Stock Option exercise Acquire M No No 179.66 1,392 250.09K 13,303

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

93.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 624 551 +13.2%
Opened positions 122 75 +62.7%
Closed positions 49 56 -12.5%
Increased positions 210 191 +9.9%
Reduced positions 217 210 +3.3%
13F shares
Current Prev Q Change
Total value 17.37B 13.49B +28.7%
Total shares 46.93M 46.55M +0.8%
Total puts 225.7K 221.6K +1.9%
Total calls 194.8K 146.7K +32.8%
Total put/call ratio 1.2 1.5 -23.3%
Largest owners
Shares Value Change
Vanguard 5.91M $2.19B +14.6%
BLK Blackrock 4.94M $1.83B -11.7%
FMR 2.56M $946.41M +26.0%
STT State Street 1.9M $702.39M +65.0%
IVZ Invesco 1.44M $533.72M +29.6%
Massachusetts Financial Services 1.44M $532.1M +4.4%
Kayne Anderson Rudnick Investment Management 1.4M $516.79M +10.8%
William Blair Investment Management 978.48K $361.96M -1.4%
Geode Capital Management 876K $323.13M +48.5%
AMP Ameriprise Financial 841.03K $311.08M -7.4%
Largest transactions
Shares Bought/sold Change
Vanguard 5.91M +754.56K +14.6%
STT State Street 1.9M +748.21K +65.0%
BLK Blackrock 4.94M -656.2K -11.7%
Marshall Wace 282.73K -634.33K -69.2%
FMR 2.56M +527.73K +26.0%
IVZ Invesco 1.44M +329.43K +29.6%
Geode Capital Management 876K +286.06K +48.5%
Westfield Capital Management 0 -262.66K EXIT
Epoch Investment Partners 34.32K -218.88K -86.4%
Ariel Investments 221.1K -189.97K -46.2%

Financial report summary

?
Risks
  • Contract development and manufacturing services create a risk of liability.
  • Charles River customers’ failure to receive or maintain regulatory approval for their product candidates could negatively impact Charles River’s revenue and profitability.
  • Charles River’s CDMO business, financial condition and results of operations may be adversely affected if the products Charles River manufactures for its customers do not gain market acceptance.
  • Charles River has various competitors in the CDMO market which could result in a decrease in the fees paid for Charles River’s services and may adversely affect its results of operations and financial condition.
  • Manufacturing services are highly complex and failure to provide quality and timely services to Charles River’s CDMO customers, could adversely impact its business.
  • CDMO operations are dependent upon the supply of necessary raw materials and supplies from third parties, and any inability to obtain such raw materials or supplies could adversely impact Charles River’s business, results of operations and financial condition.
  • The failure to successfully obtain, maintain and enforce intellectual property rights and defend against challenges to intellectual property rights could adversely affect us.
Management Discussion
  • RMS revenue increased $60.2 million due primarily to higher research model product revenue across all geographies, most notably North America and China, as we recovered from the impact of the COVID-19 pandemic compared to the corresponding period in 2020 when many of our academic clients experienced closures; higher research model services revenue, specifically
  • our RADS and GEMS business; the acquisition of Cellero, which contributed $2.2 million to product revenue; and the effect of changes in foreign currency exchange rates.
  • RMS operating income increased $38.8 million compared to the corresponding period in 2020. RMS operating income as a percentage of revenue for the three months ended June 26, 2021 was 24.1%, an increase of 2080 bps from 3.3% for the corresponding period in 2020. Operating income and operating income as a percentage of revenue increased primarily due to the contribution of higher revenue described above as we recovered from the COVID-19 pandemic.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: analytical, ASC, bps, Certification, david, duly, Furnished, half, Inline, July, Label, lapse, Linkbase, payout, Schema, seamlessly, smith, statute, Taxonomy, thereunto, tied, undersigned, Vigene, XBRL
Removed: expand, expiring, Forint, Hungarian, initial, ranged, review, state